SOURCE: Atossa Genetics, Inc.

Atossa Genetics, Inc.

August 06, 2013 16:01 ET

Atossa Genetics to Announce Second Quarter 2013 Results on Wednesday, August 14, 2013

SEATTLE, WA--(Marketwired - Aug 6, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, today announced that it will issue financial results and corporate highlights for the quarter ended June 30, 2013, following the close of market on Wednesday, August 14, 2013.

Management will host a conference call on Wednesday, August 14, 2013, at 4:45 pm Eastern time to review financial results and corporate highlights, including a slide presentation by Dr. Steven C. Quay, Chairman, Chief Executive Officer and President. Participating on the call in addition to Dr. Quay will be Kyle Guse, CFO and General Counsel, and Chris Destro, Vice President of Sales and Marketing. Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. may dial 866-652-5200 or 412-317-6060 for international callers. All callers should ask for the Atossa Genetics conference call. For your convenience, you may pre-register for the call by clicking here:

The conference call and slides will also be available through a live webcast at

A replay of the call will be available one hour after the end of the call through September 16, 2013, and can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international). The replay conference ID number is 10031764.

About Atossa Genetics

Atossa Genetics, Inc. is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, the National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa, please visit For additional information on the ForeCYTE test and the National Reference Laboratory for Breast Health, please visit

Contact Information

  • Contact:

    Atossa Genetics, Inc.
    Kyle Guse
    CFO and General Counsel
    (O) 800-351-3902
    Email Contact

    MBS Value Partners
    Matthew D. Haines (Investors)
    Managing Director
    (O) 212-710-9686
    Email Contact

    JQA Partners
    Jules Abraham (Media)
    (O) 917-885-7378
    Email Contact